Skip to main content
. 2022 May 3;13:180. doi: 10.1186/s13287-022-02848-6

Table 2.

The percentage of patients with HbA1c levels of < 7.0% and daily insulin reduction of ≥ 50% at 9–48 weeks of follow-up

UC-MSCS (% of patients) PLACEBO (% of patients) p-value
9 weeks 8.89 2.27 0.3607
20 weeks 15.56 9.09 0.3542
32 weeks 15.56 9.09 0.3542
48 weeks 20.00 4.55 0.0268